Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2725 participants.
Also called NCT02164864
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,725 participants
- Sponsor
- Registry
-
NCT02164864 -
2013-003201-26
-
- Other papers using this trial's data
- Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI
- Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation
- Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial
- Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, Czechia, Denmark, Finland, France, Germany, Greece, Hong Kong SAR China, Hungary, India, Ireland, Israel, Italy, Japan, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Russia, Singapore, Slovakia, Slovenia, South Korea, Spain, Sweden, Taiwan, Thailand, Türkiye, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02164864. Randomized; no masking; primary purpose treatment. Start 2014-07-22 (actual); primary completion 2017-06-05 (actual). Results posted on 2018-07-31.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)
- Condition
- Atrial Fibrillation
- Condition
- Percutaneous Coronary Intervention
- Intervention (Drug)
- Dabigatran Etexilate 110mg
- Intervention (Drug)
- Warfarin 3mg
- Intervention (Drug)
- Aspirin
- Intervention (Drug)
- Dabigatran Etexilate 150mg
- Intervention (Drug)
- Clopidogrel or Ticagrelor
- Intervention (Drug)
- Clopidogrel or Ticagrelor
- Intervention (Drug)
- Warfarin 5mg
- Intervention (Drug)
- Clopidogrel or Ticagrelor
- Intervention (Drug)
- Warfarin 1mg
- Lead sponsor
- Boehringer Ingelheim
Record details
- Record id
cardio:ct-nct02164864- Content hash
869c9a59323717f85b97ceed7d76a8e949212b255484361d124ff5b44b14daa8